PAPAIJV
PROF

Paragon Associates & Paragon Associates II Joint Venture’s Profound Medical PROF Stock Holding History

Paragon Associates & Paragon Associates II Joint Venture’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.79M Buy
+276,001
New +$1.91M 2.43% 12

Other funds holding PROF

Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $476M AUM
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Paragon Associates & Paragon Associates II Joint Venture's PROF Position: Q1 2026 in Review

Paragon Associates & Paragon Associates II Joint Venture opened a new position in Profound Medical (PROF) in Q1 2026: 276,001 shares worth $1.79M. The stake represents 2.43% of the portfolio and ranks #12 among its holdings.

57 funds tracked by Wall St. Rank hold PROF as of Q1 2026.

  • Paragon Associates & Paragon Associates II Joint Venture held 276,001 shares of Profound Medical worth $1.79M as of Q1 2026.
  • Profound Medical was a new Paragon Associates & Paragon Associates II Joint Venture position in Q1 2026.
  • Profound Medical made up 2.43% of Paragon Associates & Paragon Associates II Joint Venture's portfolio in Q1 2026, its #12 holding.
  • 57 funds tracked by Wall St. Rank held Profound Medical as of Q1 2026.

Based on Paragon Associates & Paragon Associates II Joint Venture's 13F filing for Q1 2026, filed 15 May 2026.